RPL24 as a potential prognostic biomarker for cervical cancer treated by Cisplatin and concurrent chemoradiotherapy

Frontiers in Oncology

Oncology

Dedong Yu¹  Xuelian Bai¹  Lifeng Zhao¹  Yun Wu¹  Cheng Ming²  Xiaomin Wang³ 

[1] Department of Oncology, Baotou Central Hospital, Baotou, China;Department of Oncology, Baotou Central Hospital, Inner Mongolia Medical University, Baotou, China;Institute of Translational Medicine, Baotou Central Hospital, Baotou, China;

关键词: cervical cancer;    RPL24;    concurrent chemoradiotherapy;    prognosis;    biomarker;   

DOI  :  10.3389/fonc.2023.1131803

 received in 2022-12-26, accepted in 2023-09-05,  发布年份 2023

来源: Frontiers

【 摘 要 】

Cervical carcinoma (CC) is the one of most common gynecologic cancers worldwide. The ribosomal proteins (RPs) are essential for ribosome assembly and function, and it has been verified that the abnormal expression of RPs was closely associated with tumorigenesis. In this study, we found that the RP large subunit 24 (RPL24) expression level was upregulated after the CC cell lines SiHa and HeLa were treated with Cisplatin (CDDP) in vitro. Simultaneously, a nude mouse xenograft model was used to examine the effect of RPL24 on tumor growth in vivo, which showed that overexpression of RPL24 can suppress tumor growth. Furthermore, we proved that RPL24 expression increased after CC patients were treated with concurrent chemoradiotherapy (CCRT), and the higher expression of RPL24 predicted a better prognosis using clinical data from 40 CC patients, verified via the Kaplan-Meier Plotter and LOGpc. These results revealed that RPL24 can be considered a potential biomarker to predict the prognosis of CC patients and assess CCRT efficacy.

【 授权许可】

Unknown   
Copyright © 2023 Ming, Bai, Zhao, Yu, Wang and Wu